peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

Year-End Release 2009

10 Feb 2010, 08:40
Regulatory information
This is a summary of the full Swedish report. For a full account of the company’s operations, refer to the Swedish report.

Financial information
• Net sales for the Group amounted to SEK 3,0 M (0,1)
• The Group reported a loss of SEK 15,8 M (loss: 2,6)
• The Group’s operating loss amounted to SEK 15,7 M (loss: 15,9)
• The loss per share was SEK 4,1 SEK (loss: 0,67)

Year in brief
• Clinical results with Hansa Medical’s HMD-301 diagnostic method were published in Clinical Infectious Diseases
• Hansa Medical and Axis-Shield entered a development and license agreement regarding HMD-301 (HBP), a method for the diagnosis of severe sepsis
• Hansa Medical and Inverness Medical Innovations entered into a partnership agreement for the development of anti-alpha-11, a new antibody based pharmaceutical to treat rheumatoid arthritis
• Hansa Medical received SEK 0.5 M in financing from VINNOVA for its TAME research project to evaluate new treatment methods for autoimmune diseases
• The alpha-10 research project was sold to Xintela AB
• The Board of Directors was re-elected, and the Articles of Association were amended at the Annual General Meeting.

CEO’s comments“During 2009, we achieved substantial success with the anti-alpha-11 and HMD-301 projects in both business and development terms. The contracts with Inverness and Axis-Shield provide Hansa Medical with invaluable access to technology and experience and accelerate product development of anti-alpha-11 and HMD-301. In the short term, we will receive milestone payments from our partners, if we succeed with further development. Above all, we are now working jointly to realize the long term attractive business opportunities for these two promising projects: market introduction of the HMD-301 diagnostic method and identification of an anti-alpha-11 drug candidate ready for licensing to a commercially established pharmaceutical company,” says Emanuel Björne, CEO of Hansa Medical AB